

Table of contents

Subject	Page No.
Figure S1	S2
Figure S2	S3
Figure S3	S3
1D and 2D NMR spectra of compounds 1-4, 9, 12, 13, 14, 16-32	S4-S45

Figure S1: ESI-TOF LC-MS of Q β -glycan conjugate **1** with peaks from Q β coat protein monomer and the respective Q β -glycan conjugates marked. Assuming Q β monomer and Q β -glycan conjugates have the same ionizing efficiencies, the ion intensities of the peaks were used to estimate the relative quantities of each species. On average, there were 1.61 glycan **1** per Q β monomer, which corresponds to 290 copies of glycan **1** per Q β particle.




Figure S2: MALDI-TOF MS of BSA-glycan **1** conjugate. Based on the molecular weight difference between the BSA-glycan **1** conjugate and unmodified BSA, the number of glycan **1** per BSA was calculated to be 15.




Figure S3. The titers of anti-glycan antibody subtypes elicited by Q β -glycan **1** from mice (day 35, 4 μ g). ELISA titers were calculated as the highest fold of serum dilution that gave optical density of 0.1 higher than the background in ELISA assays. Each symbol represents one mouse, with the long horizontal line for each group representing the mean value of each group.






Table S1. a) Anti-glycan 1IgG ELISA titers from rabbits immunized with Q β -glycan 1 conjugate. b) Anti-*S. Paratyphi A* OPS IgG ELISA titers from rabbits immunized with Q β -glycan 1 conjugate.

a)	anti-glycan 1 IgG (ELISA unit)			
	Pre-immunization	Day 35 post immunization	Day 49 post immunization	Day 56 post immunization
Rabbit 1	<2,000	1.2 x 10 ⁷	1.4 x 10 ⁷	1.4 x 10 ⁷
Rabbit 2	<2,000	1.6 x 10 ⁷	2.1 x 10 ⁷	1.2 x 10 ⁷


b)	anti-Paratyphi A OPS IgG (ELISA unit)	
	Pre-immunization	Day 56 post immunization
Rabbit 1	181	1.8 x 10 ⁶
Rabbit 2	84	2.4 x 10 ⁶






^1H , ^{13}C and DEPT-135 NMR spectra of 2-aminoethyl (3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)- α -D-galactopyranoside (**1**) (D₂O, 500 MHz).




2D COSY and HSQC NMR spectra of 2-aminoethyl (3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(2,3-di-O-acetyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(α -L-rhamnopyranosyl)-(1 \rightarrow 3)- α -D-galactopyranoside (**1**) (D₂O, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(α -D-glucopyranosyl)-(1 \rightarrow 6)]- α -D-galactopyranoside (**2**) (D_2O , 500 MHz).




2D COSY and HSQC NMR spectra of 2-azidoethyl (3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(α -D-glucopyranosyl)-(1 \rightarrow 6)]- α -D-galactopyranoside (**2**) (D₂O, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[α -D-glucopyranosyl)-(1 \rightarrow 6)]- α -D-galactopyranoside (**3**)(D_2O , 500 MHz).




2D COSY and HSQC NMR spectra of 2-azidoethyl (α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(α -D-glucopyranosyl)-(1 \rightarrow 6)]- α -D-galactopyranoside (**3**)(D₂O, 500 MHz).










^1H , ^{13}C and DEPT-135 NMR spectra of ethyl 2,4-di-*O*-benzyl-3,6-dideoxy-1-thio- β -D-ribohexopyranoside (**4**) (CDCl_3 , 500 MHz).






^1H , ^{13}C and DEPT-135 NMR spectra of ethyl 2,4-di-*O*-benzyl-3-*O*-*p*-methoxybenzyl-6-*O*-(tert-butyltrimethylsilyl)-1-thio- β -D-galactopyranoside(**9**) (CDCl_3 , 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of ethyl 3,6-di-*O*-(tert-butyldimethylsilyl)-1-thio- β -D-glucopyranoside (**12**)(CDCl_3 , 500 MHz).




¹H, ¹³C and DEPT-135 NMR spectra of ethyl 2,4-di-O-benzyl-3,6-di-O-(tert-butyl dimethylsilyl)-1-thio-β-D-glucopyranoside (**13**) (CDCl₃, 500 MHz).





^1H , ^{13}C and DEPT-135 NMR spectra of ethyl 2,4-di-*O*-benzyl-1-thio- α -D-glucopyranoside (**14**) (CDCl_3 , 500 MHz).




¹H, ¹³C and DEPT-135 NMR spectra of ethyl 3-*O*-*p*-methoxybenzyl-6-*O*-(tert-butyldimethylsilyl)-1-thio-β-D-galactopyranoside (**16**) (CDCl₃, 500 MHz).




¹H, ¹³C and DEPT-135 NMR spectra of ethyl (2,4-di-*O*-benzyl-3,6-dideoxy- β -D-ribohexopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**17**) (CDCl₃, 500 MHz).





2D COSY and HMQC NMR spectra (selected regions) of ethyl (2,4-di-*O*-benzyl-3,6-dideoxy- β -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**17**) (CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of ethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribohexopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**18**) (CDCl_3 , 500 MHz).




2D COSY and HMQC NMR spectra (selected regions) of ethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**18**) (CDCl₃, 500 MHz).






^1H , ^{13}C and DEPT-135 NMR spectra of ethyl (2,4-di-*O*-benzyl-3,6-di-*O*-(tert-butyl-dimethylsilyl)- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**19**)(CDCl_3 , 500 MHz).





2D COSY and HSQC NMR spectra (selected regions) of ethyl (2,4-di-*O*-benzyl-3,6-di-*O*-(tert-butylidimethylsilyl)- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**19**)(CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of ethyl (2,4-di-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**20**)(CDCl_3 , 500 MHz).





2D COSY and HSQC NMR spectra (selected regions) of ethyl (2,4-di-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**20**)(CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of ethyl (2,4-di-*O*-benzyl-3,6-di-phenoxythiocarbonyl- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**21**) (CDCl₃, 500 MHz).




2D COSY and HSQC NMR spectra (selected regions) of ethyl (2,4-di-*O*-benzyl-3,6-di-phenoxythiocarbonyl- α -D-glucopyranosyl)-(1 \rightarrow 3)-2-*O*-acetyl-4,6-di-*O*-benzyl-1-thio- α -D-mannopyranoside (**21**)(CDCl₃, 500 MHz).








^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl 2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**22**)(CDCl₃, 500 MHz).




^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (4-*O*-acetyl-2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**23**) (CDCl_3 , 500 MHz).





2D COSY and HSQC spectra (selected regions) of 2-azidoethyl (4-*O*-acetyl-2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**23**) (CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (2,3-O-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-O-benzyl- α -D-galactopyranoside (**24**) (CDCl_3 , 500 MHz).





2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**24**) (CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribohexopyranosyl)-(1 \rightarrow 3)-(2-*O*-acetyl-4,6-di-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**25**) (CDCl_3 , 500 MHz).




2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(2-*O*-acetyl-4,6-di-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranoside (**25**) (CDCl₃, 500 MHz).








¹H, ¹³C and DEPT-135 spectra of 2-azidoethyl 2,4-di-*O*-benzyl-3-*O*-*p*-methoxybenzyl-6-*O*-(*tert*-butyldimethylsilyl)- α -D-galactopyranoside (**26**)(CDCl₃, 500 MHz).




^1H , ^{13}C and DEPT-135 spectra of 2-azidoethyl 2,4-di-*O*-benzyl-3-*O*-*p*-methoxybenzyl- α -D-galactopyranoside (**27**)(CDCl_3 , 500 MHz).




^1H , ^{13}C and DEPT-135 spectra of 2-azidoethyl (2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)-2,4-di-*O*-benzyl- α -D-galactopyranoside (**28**)(CDCl_3 , 500 MHz).




2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)-2,4-di-*O*-benzyl- α -D-galactopyranoside (**28**)(CDCl₃, 500 MHz).









¹H, ¹³C and DEPT-135 NMR spectra of 2-azidoethyl (4-*O*-acetyl-2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**29**) (CDCl₃, 500 MHz).




2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (4-*O*-acetyl-2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**29**) (CDCl₃, 500 MHz).




29




^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (2,3-O-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-O-benzyl- α -D-galactopyranoside (**30**)(CDCl₃, 500 MHz).





2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**30**)(CDCl₃, 500 MHz).







^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribohexopyranosyl)-(1 \rightarrow 3)-(2-*O*-acetyl-4,6-di-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**31**) (CDCl_3 , 500 MHz).





2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2,4-di-*O*-benzyl-3,6-dideoxy- α -D-ribo-hexopyranosyl)-(1 \rightarrow 3)-(2-*O*-acetyl-4,6-di-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (31) (CDCl₃, 500 MHz).





^1H , ^{13}C and DEPT-135 NMR spectra of 2-azidoethyl (2-*O*-acetyl-3,4,6-tri-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**32**) (CDCl_3 , 500 MHz).



2D COSY and HSQC NMR spectra (selected regions) of 2-azidoethyl (2-*O*-acetyl-3,4,6-tri-*O*-benzyl- α -D-mannopyranosyl)-(1 \rightarrow 4)-(2,3-*O*-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)]-2,4-di-*O*-benzyl- α -D-galactopyranoside (**32**) (CDCl₃, 500 MHz).

